What type of study is this?

September 5, 2025

Bruton’s tyrosine kinase (BTK) inhibitors: an updated patent review (2019-2024)

Key Points

The review illustrates that BTK inhibitors are key in targeting B-cell malignancies, potentially improving treatment outcomes.
With six approved BTK inhibitors, the landscape of drug development has expanded significantly over recent years.
Clinical research is ongoing for several innovative BTK inhibitors, including PROTAC, showcasing their evolving therapeutic prospects.
The patent review covers the period from 2019 to 2024, reflecting the rapid advancements in this field.

Abstract

Introduction Bruton's tyrosine kinase (BTK) is a critical regulator in the pathogenesis of B-cell malignancies, inflammatory diseases, and autoimmune diseases. In recent years, BTK inhibitors have been a hot topic in drug development, with promising therapeutic prospects. Six BTK inhibitors have been approved, and several (including PROTAC) are undergoing clinical research.

KI fragen

Bookmark

Cite This Study

Cui et al. (Fri,) studied this question.

synapsesocial.com/papers/68bb421a2b87ece8dc95885c https://doi.org/https://doi.org/10.1080/13543776.2025.2554638

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark